Drug Profile
Alunacedase alfa - Apeiron Biologics
Alternative Names: APN-01; GSK-2586881; Recombinant-human-soluble-angiotensin-converting-enzyme-2-Apeiron-Biologics; rhACE2; rhACE2-Apeiron-BiologicsLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Apeiron Biologics
- Developer Apeiron Biologics; GlaxoSmithKline; University of British Columbia
- Class Anti-ischaemics; Antihypertensives; Antineoplastics; Antivirals; Cardiovascular therapies; Heart failure therapies; Recombinant proteins
- Mechanism of Action ACE stimulants; Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Acute lung injury; Adult respiratory distress syndrome; COVID 2019 infections; Pulmonary arterial hypertension
- Discontinued Cancer; Diabetic nephropathies; Heart failure; Hypertension; Myocardial infarction
Most Recent Events
- 03 Nov 2022 Alunacedase alfa - Apeiron Biologics is available for licensing as of 03 Nov 2022. https://www.invios.com/
- 03 Nov 2022 Adverse events and pharmacodynamics data from a phase I trial in COVID-2019 infections (In volunteers) released by APEIRON Respiratory Therapies
- 27 May 2022 Apeiron Biologics completes a phase I trial in COVID-2019 infections (In volunteers) in Austria (Inhalation) (NCT05065645)